Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 4:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 5,153 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 2 Interventional Results available

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

NCT03149029
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Conditions
Melanoma
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Tuscon, Arizona • Los Angeles, California + 6 more
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, conventional surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Conditions
Melanoma (Skin)
Interventions
dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Renal Cell Carcinoma
Interventions
DSP-7888 Dosing Emulsion
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Nivolumab, Embolization Therapy
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Unresectable or Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
46
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, lymphokine-activated killer cells
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Staten Island, New York
Conditions
Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor
Interventions
Carboplatin, Filgrastim, Ifosfamide, Laboratory Biomarker Analysis, Paclitaxel
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
85
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Conditions
Melanoma, Herpetic Infection
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Melanoma Biomarker Study

NCT00348088
Conditions
Metastatic Melanoma
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Conditions
Neuroendocrine Tumors
Interventions
Octreotide, LAR Lanreotide, Questionnaires
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
cilengitide, temozolomide, radiation therapy, laboratory biomarker analysis, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis and Treatment of Pheochromocytoma

NCT00001229
Conditions
Pheochromocytoma
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions
sunitinib malate
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota